EMEA-001407-PIP01-12-M03
Key facts
| Invented name |
Opdivo
|
| Active substance |
nivolumab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0432/2020
|
| PIP number |
EMEA-001407-PIP01-12-M03
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001407-PIP01-12-M03
|
| Compliance opinion date |
21/01/2022
|
| Compliance outcome |
positive
|